Hungary/Austria: Schoenherr advises Ceres Pharma on acquisition of Hungarian companies Innopharm & Vitaplus and their Austrian subsidiary
Schoenherr advised Ceres Pharma NV, a Belgium-based pharmaceutical company, on the acquisition of the Hungarian pharmaceutical companies VitaPlus Kft and Innopharm Kft., including their Austrian subsidiary Innopharm GmbH.
The firm provided comprehensive legal support to Ceres Pharma, including the due diligence process, structuring of the transaction, negotiation of the share purchase agreement, FDI and merger control assessment as well as FDI application.
Based in Belgium, Ceres Pharma is a pharmaceutical company founded in 2017 by Mario Debel and Alychlo and acquired in 2021 by Naxicap Partners. Ceres Pharma is active in the development and distribution of drugs, medical devices, biocides, cosmetics, qualitative food supplements and pharmaceutical preparations in Benelux, Italy and Central and Eastern Europe.
VitaPlus is a leading Hungarian pharmaceutical company active in the development and distribution of innovative and value-for-money food supplements and medical devices in Hungary and beyond.
The Schoenherr team advising on the Hungarian aspects of the matter was led by Kinga Hetényi (partner) and further consisted of Adrián Menczelesz (attorney at law), Áron Hegyi (attorney at law), Márk Kovács (attorney at law), Ákos Kovács (associate), Zsófia Rideg (associate) and Noémi Csiki (associate). The team was supported by Teresa Waidmann (counsel), Alfred Amann (attorney at law), Alexander Pabst (attorney at law) and Verena Krikler (associate), who covered the Austrian aspects of the acquisition.